TY - JOUR T1 - Impact of COVID-19 Pandemic on Surgical Breast Cancer Patients Undergoing Neoadjuvant Therapy: A Multicentric Study JF - Anticancer Research JO - Anticancer Res SP - 4535 LP - 4542 DO - 10.21873/anticanres.15265 VL - 41 IS - 9 AU - GIANLUCA VANNI AU - MARCO PELLICCIARO AU - FRANCESCA COMBI AU - SIMONA PAPI AU - MARCO MATERAZZO AU - SILVIA SEGATTINI AU - STEFANO RIZZA AU - MARCELLO CHIOCCHI AU - TOMMASO PERRETTA AU - ROSARIA MEUCCI AU - ILARIA PORTARENA AU - CHIARA ADRIANA PISTOLESE AU - BENEDETTO IELPO AU - MICHELA CAMPANELLI AU - GIORGIO LISI AU - AGOSTINO CHIARAVALLOTI AU - GIOVANNI TAZZIOLI AU - ORESTE CLAUDIO BUONOMO Y1 - 2021/09/01 UR - http://ar.iiarjournals.org/content/41/9/4535.abstract N2 - Background/Aim: Due to the SARS-CoV-2 pandemic, many scientific committees proposed neoadjuvant therapy (NACT) bridging treatment as a novel strategy and indication. The aim of the study was to evaluate the impact of COVID-19 pandemic on breast cancer patients undergoing NACT. Patients and Methods: All breast cancer patients referred to two Breast Units during COVID-19-pandemic were enrolled. Results: Out of 814 patients, 43(5.3%) were enrolled in the COVID-19-group and compared with 94 (7.9%) similar Pre-COVID-19 patients. We observed a reduction in the number of patients undergoing NACT, p=0.0019. No difference was reported in terms of clinical presentation, indications, and tumor response. In contrast, a higher number of vascular adverse events was reported (6.9% vs. 0% p=0.029). Immediate breast cancer reconstructions following invasive surgery suffered a significant slowdown (5.9% vs. 47.7%, p=0.019). Conclusion: COVID-19 caused a reduction in the number of patients undergoing NACT, with no changes in terms of indications, clinical presentation, and tumor response. Furthermore, there was an increased incidence of vascular events. ER -